On This Day in Health: May 1, 2019
On May 1, 2019, the U.S. Food and Drug Administration approved Dengvaxia, the first dengue vaccine licensed in the United States. Developed by Sanofi Pasteur, it was authorized for children and adolescents aged nine through sixteen who had laboratory-confirmed previous dengue infection and lived in areas where the disease was endemic. Those conditions were central to the decision. The vaccine was not cleared for everyone worried about mosquito bites, nor for travelers seeking protection before a holiday. The milestone offered a new preventive option to a narrowly defined population while recognizing an unusual and important safety problem.
Dengue is caused by four related viruses transmitted primarily through infected Aedes mosquitoes. Infection can produce fever, headache and severe body aches, and some cases progress to dangerous complications. Recovering from one dengue infection does not provide reliable protection against all the other types. A later infection with a different type can carry a greater risk of severe illness. This complicated immune relationship made vaccine development particularly challenging: a useful vaccine needed to account for both the virus types and the person's earlier exposure. Communities facing sustained transmission, including Puerto Rico and other U.S. territories, had reason to seek protection beyond mosquito control alone.
The FDA's review supported vaccination in people with evidence of an earlier infection, but identified a different balance of risks in those never previously infected. In that group, receiving the vaccine and then encountering dengue naturally could increase the risk of severe disease. The original authorization therefore required previous infection to be established through laboratory evidence or an appropriate documented history. The live, tetravalent vaccine targeted all four virus types, yet its potential benefit depended on screening the recipient first. Eligibility was part of the medical intervention itself. A vaccination program needed a dependable way to distinguish people likely to benefit from those for whom the same product could create additional danger.
The 2019 approval should also be distinguished from later recommendations and availability. The U.S. Advisory Committee on Immunization Practices issued its dengue vaccination recommendations in 2021. In 2024, Sanofi announced that production would be discontinued because of limited global demand; the product subsequently became unavailable in the United States. Those later developments do not change the date of its original approval, but they prevent the anniversary from being mistaken for present-day advice to obtain it. May 1 remains a revealing episode in public health: a vaccine can be a significant scientific advance while still requiring careful selection, testing and practical delivery. The history demonstrates why the details accompanying an approval matter as much as the headline.
The original US approval covered ages nine through sixteen with confirmed previous infection.
Dengue involves four related virus types, complicating both natural immunity and vaccine development.
Screening was necessary because vaccination could raise later severe-disease risk in previously uninfected recipients.
The 2019 decision did not authorize routine vaccination of travelers from non-endemic areas.
US vaccination recommendations followed in 2021, separately from the original FDA approval.
The manufacturer later discontinued production; the anniversary describes a historical authorization.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.